Autolus Therapeutics (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$1.60
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.60
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.18 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.66M
Market Cap
$428.49M
Enterprise Value$675.95M
Total Cash (Recent Filing)$300.71M
Total Debt (Recent Filing)$351.59M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 14, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding266,143,280
10 Day Avg. Volume1,496,455
30 Day Avg. Volume1,657,714
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.75
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue8.97
Enterprise Value/Gross Profit-32.22
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$9.67Price Target Upside504.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$129.39M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And ManufacturingAnalyst anticipates that activating additional treatment centers and optimizing manufacturing could increase patient volumes and help the company progress toward positive gross margins as revenues grow.
Pediatric And Earlier-line ExpansionAnalyst highlights planned pediatric study expansion and collaborations with major oncology groups that support moving Aucatzyl earlier in treatment and potential inclusion in pediatric treatment guidelines.
Safety ProfileAnalyst reports physicians at key opinion leader events preferred Aucatzyl for its improved safety profile and low rates of cytokine release syndrome and neurotoxicity, supporting use in patients who cannot undergo stem cell transplant.
Bears Say
Guidance Miss And Valuation PressureAnalyst notes a guidance miss has contributed to the stock trading near cash value, reflecting investor concern about revenue momentum and valuation risk.
Reimbursement And Patient StartsAnalyst notes a reimbursement coding change temporarily slowed patient starts, creating uncertainty around revenue trends and adoption rates.
Timing Of ProfitabilityAnalyst points to continued uncertainty about the timing of achieving positive gross margins, which may weigh on the stock until clear profitability milestones are reached.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was $1.18 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is $428.49M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is May 14, 2026 which is in 6 days.
How were Autolus Therapeutics’s earnings last quarter?
Autolus Therapeutics released its earnings results on Mar 27, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.08.
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,143,280 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Autolus Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -6.202%.
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (504.17% Upside)
$9.67 (504.17% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 147.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.88%
12-Months-Change
Fundamentals
Return on Equity
-99.00%
Trailing 12-Months
Asset Growth
-24.74%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: strong commercial launch momentum for AUCATZYL with $74.3M 2025 product sales, robust real-world efficacy and safety (ROCCA), regulatory approvals, and an active, value-creating clinical pipeline and clear guidance for 2026 revenue growth and positive gross margins. Offsetting these positives are materially higher costs in Q4, a large year-over-year increase in net loss, a nearly 49% decline in cash balance to $300.7M, and limited near-term expansion in EU revenues. The company is prioritizing scale and operating efficiencies and expects cash to fund operations into Q4 2027, but execution on margin improvements, enrollment/readouts, and potential financing or revenue realization will be critical.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$9.67
▲(504.17% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.36% Mutual Funds
0.31% Other Institutional Investors
98.67% Public Companies and Individual Investors